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Three hundred and seventeen patients meeting the diagnostic criteria for immune 
thrombocytopenia presented to Red Cross War Memorial Children’s Hospital 
between 1991 and 2011. We retrospectively reviewed these patients in order to 
describe patient demography, the natural history of the disease, and different 
approaches to diagnosis and management. There were 162 males and 155 female 
patients. The median age of onset was 3.48 years old (IQR 1.66-6.36).  In the 4 
weeks preceding presentation, 98 (31%) patients had a viral illness. The median 
presenting platelet count was 7 x 109/L (IQR 3-14.5). Petechiae were the most 
common clinical sign at presentation (58%; 184/317). None of the patients presented 
with intracranial haemorrhages. The majority of patients in the study were admitted 
(234/317; 74%) with a median stay of 4 days (IQR 0-6). Bone marrow aspirates 
(BMA) were performed in 188 patients (59%). There was a reduction in BMA from 
1991-2000 to 2001-2011 (p<0.001). There was an increase in the percentage of 
patients treated from 1991-2000 (77/170; 44%) to 2001-2011 (99/147, 67% p< 
0.001). Resolution occurred in 75% of patients with a median time to resolution of 31 
days (IQR 11-73 days).  When we analysed the “survival estimate” from the 2 
decades, despite differing rates of BMA, treatment rates and regimens, there was no 
statistical difference in resolution.  
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Chapter 1: Literature Review 
 
Immune Thrombocytopenia (ITP) or Immune Thrombocytopenic Purpura, also 
known as Idiopathic Thrombocytopenic Purpura is one of the commonest causes of 
thrombocytopenia (low platelets) in children. This condition has seen vast changes in 
definition, management options and treatment strategies in the last 10 years. As 
research has led to a better understanding of ITP, the need for standardisation has 
become more apparent, leading to international collaboration with regard to 
recommendations and building registries of patients.  
Thus far most of the work has been spearheaded by developed countries namely 
United States of America, the United Kingdom (UK) and Nordic countries. Our place 
as a developing country in Sub-Saharan Africa, with perhaps different needs, 
demographics and resources has not been examined. The aim of the study is to 
review patients presenting to Red Cross War Memorial Children’s Hospital 
(RCWMCH) in Cape Town, to understand the local demographic and the natural 
history of the disease, and to examine our position in the diagnostic and 
management debate. 
 
The literature review which was done in June 2013 and repeated in November 2015, 
was done using Pubmed, Ebscohost,The Cochrane library and Web of science. The 
terms of the search included MeSh words: [ITP] [Child] [paediatric/pediatric] 
[immune/idiopathic thrombocytopenia] [Africa] and free text. The bibliographic 




ITP is a well recognised cause of thrombocytopenia in children, defined as a platelet 
count less than < 100 x 109/l. This threshold was established by the International 
Working Group (IWG) at the Vicenza Consensus Conference, held in Italy in 2007.1 
The previous cut-off of <150 x 109/l was no longer recommended for 2 reasons. 
Studies  from Iran and Uganda found that frequently in healthy people the platelet 
count ranged from 100-150 x 109/l.1,2,3 Furthermore, a cohort prospective study in 
healthy individuals with platelet counts between 100-150 x  109/l found that the 10 
year probability of developing severe thrombocytopenia was only 6.9% (with a 95% 
CI of 4-12%).4  
The nomenclature of ITP changed at the conference. Previously the term “Idiopathic” 
Thrombocytopenia was used; the expert panel preferred to encourage the use of 
“Immune” Thrombocytopenia thereby stressing the pathophysiology of the disease.1  
The IWG also described 2 forms of ITP i.e. primary and secondary ITP; “Primary” 
denoting the absence of an underlying cause, and therefore being a diagnosis of 
exclusion. “Secondary” ITP are those diseases which have an immune mechanism 
as well as another causative stimulus e.g. drugs, systemic lupus erthymatosus.1,5 
Different phases and severities of ITP were proposed. All new cases of patients with 
ITP were to be labelled as a “Newly Diagnosed ITP”. In the event that symptoms 
persisted, or recurred after 3 months (to a maximum of 12 months) then the new 
nomenclature would be   “Persistent” ITP. Were the disease process to continue for 
more than 12 months, the patient was then to be categorised as having “Chronic” 
ITP.  
Response to treatment or resolution was also defined. The IWG did acknowledge 
that while the clinical picture of the patient and his/her symptomatology was crucial 
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to assess response/remission, for the sake of uniformity cut-off values needed to be 
included. If a patient’s platelet count was greater than 100 x 109/l with no bleeding, 
then they were said to have attained a “Complete Response”. Response was defined 
by a platelet count between 30 and 100 x 109/l as well as doubling of the baseline 
count. If a patient had neither the count between the stated range or the count had 
not doubled from baseline, then they were said to have “No response”.1
Refractory ITP was been defined in adults as failure to achieve response, or loss of 
response after a splenectomy. However in children, a splenectomy was often 
delayed and thus the IWG did not reach agreement on the definition of refractory ITP 
in children.1
Pathogenesis 
The pathogenesis of ITP is complex. It is an immune mediated disorder, 
characterised by the loss of self tolerance. ITP is caused by autoantibodies, usually 
IgG, that are directed against platelet membrane antigens e.g. glycoprotein IIb and 
IIIa. These antibody coated platelets trigger a premature destruction of the platelets, 
by the reticuloendothelial system (mainly in the spleen). The antibodies also have an 
effect against glycoproteins on the surface of megakaryocytes. These combine to 
upset the balance between production and destruction of platelets.6, 7, 8 
Antigen presenting cells (APC) are the key players in the pathway that leads to loss 
of self-tolerance. Their purpose is to internalise and break down proteins that are 
seen as antigens and then present them to T cells.7,9,10 Usually aberrant APCs that 
recognise “self” as antigenic are themselves destroyed. Some studies have shown 




T cells become activated upon recognition of platelet specific antigens on APCs.8   
The T cells release cytokines that result in antigen specific B cells. Some studies 
have shown that there is an increase ratio of Th1/Th2 cells which favours 
“autoreactive B cell development”.7,11 Some research proposes that a novel T cell, 
Th 17 produces cytokines e.g. Interleukin 17 that further favour the imbalance 
between Th1 and Th2 cells, and then also drives autoimmunity.10 The dysregulation 
of self-tolerance is further promoted by impaired T-regulatory cells, whose function is 
to decrease cell-mediated and antibody-mediated response.7, 9, 10 
Once the B cell has been induced, it produces autoantibodies to glycoproteins on 
platelets and megakaryocytes. These antibody-platelet complexes are then removed 
by Fc receptors on phagocytes, predominantly in the spleen.8 The megakaryocytes 




The cause of ITP is often unknown, however certain intrinsic (e.g. gene mutations 
affecting immune response, ethnicity) and extrinsic factors (e.g. infectious disorders, 
recent vaccines or drugs) may contribute.  
In a cohort study by Kϋhne et al. data was collected from two cohorts within the 
same time period - 90 Asian (Vietnamese) and 89 European (German and Swiss) 
children over a two year period. The sex and age distribution were similar, but there 
was a substantial difference in the rate of infection which preceded the onset of ITP. 
Infection was categorised as occurring within 14, 21 or more than 21days before the  
onset of ITP. It was non-specific in its definition including fever, upper respiratory 
tract, gastrointestinal tract or “any specific infection and immunisation”. Sixteen 
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percent of the children in Vietnam had a preceding infection as compared to 66% in 
the European cohort (p <0.001). This may support the theory that certain 
environmental or ethnic factors play a role in ITP.12  
 
A systematic review of literature around vaccines, specifically looking at the 
Measles-Mumps-Rubella (MMR) vaccine, was conducted. The time after exposure in 
the studies that were included was either not stated or between 35 days to 182 days. 
The findings were that of a low incidence of MMR–associated ITP (0.0087 to 4 cases 
per 100 000 vaccine doses). It was found that the “MMR-associated ITP is rare, self-
limiting and non-life threatening”.13 It has been reported as safe to repeat doses of 
MMR in a patient with either vaccine-related or non-vaccine related ITP, as long as 




In 1996, when researchers from the American Society of Haematology (ASH) 
published recommendations on managing ITP, the overall consensus was that the 
recommendations were lacking in clinical data and research.5,16  Soon afterwards the 
Intercontinental Childhood ITP Study Group (ICIS) in 1997 was formed. The group 
was established to promote research in the field and share patient data, thus 
increasing the pool of patients to be analysed. The group was renamed in the early 
2000s to the International Cooperative Study Group to include both paediatric and 
adult haematology. The group developed registries to study the epidemiology of 
patients with ITP, the natural history and differences in outcome based on 
management and/or interventions. The first registry was started in 1997 and “closed” 
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in 2000. The ICIS Registry 1 looked at the epidemiology of ITP. Registry 2 (2002-
2004) focused on bleeding as an outcome in ITP, and examined the platelet count as 
a risk factor for bleeding. Two current registries that are being collated are the 
PARC-ITP i.e. Paediatric and Adult Registry on Chronic ITP and The Splenectomy 
Registry.5 
Incidence 
A critical review paper estimates the incidence of ITP in children and adults at 1.9 to 
6.4 x 105 children per year based on statistical analysis of recent studies.17 
They reviewed studies in the Medline database where estimates of the incidence of 
ITP were published. Eight studies were identified, and 4 out of 8 studies were 
determined to have the most accurate estimates, based on the method of patient 
identification and study design.17 The lowest estimated incidence was 2.2 per 105 
children/year and the highest incidence estimate was 5.3 per 105 children/year. The 
4 studies that were cited were from Norway,18 Scandinavia (Nordic study),19 Britain 
(UK audit) 20 and Germany21. It is unknown whether interpretation of the data is 





The mean age of onset with children registered in the ICIS Registry 1 was 5.7 years 
(in girls 5.9 years and boys 5.5 years.)5 The peak age distribution was between 1-6 
years old. Similarly in the Nordic study nearly 80% of the children were less than 8 
years old19 and in a UK study, using the UK Childhood ITP registry, the majority were 




Most studies have shown that in the younger age groups i.e. 1-5 years old, boys 
predominated over girls,5,21,22,23 with a UK report approximating a ratio of 1.8:1 
(males to females),22 1.5:1 in a German survey21 and 1.4:1 in the Nordic study19. The 
older children either had an equal representation of boys to girls19,21 or a slight 
predominance of girls (0.8:120). A retrospective chart review from The Children’s 
Hospital in Alabama reported no difference in the gender distribution between girls 
and boys.24 They did not stratify the children into age categories and this may explain 
why their findings differed from other studies. 
Seasonal Variation 
There is conflicting data with regard to seasonal variation.  
In the Nordic19 (n=385) and German studies21 (n=323), a peak incidence in winter 
was seen. Zeller et al19 ascribes this to the increased incidence of infections in 
winter, thus increasing the number of post-infectious cases of ITP.  
An observational study using the Intercontinental Cooperative ITP Registry (n=2190) 
reported a peak occurrence during spring/early summer and a nadir in autumn. The 
authors did not explain these findings.23 
 
Preceding infections 
Infections are known to be one of the triggers for ITP.12  Various studies use different 
time frames for the time before onset of ITP; Grainger et al used a cut off of 6 weeks 
prior to onset of ITP, and reported that in 47% of cases (n=104/220), that there was 
a preceding history of a viral infection.22 The Nordic study group (n=292/501) 
reported an incidence of infection of 57.7% 4 weeks before the diagnosis of ITP.19 
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Similarly, a study from The Hospital for Sick Children in Toronto revealed that 57% of 
their participants had a recent upper respiratory tract infection. The time period was 
unspecified.25 There are few data from developing countries with regard to the 
relationship between infections and the onset of ITP, although one may expect the 
incidence to be higher. Interestingly Kϋhne et al showed a low incidence of infection 
(15%) preceding the onset of ITP, in a Vietnamese population group (n= 82).12
A retrospective study from Nigeria reported all patients (children and adults) who 
presented with ITP over an 11 year period. None of their patients had a preceding 
infection. There were only 11 patients (in total) making it neither statistically, nor 
clinically significant, because the majority of the patients were adults (n=7).26 This 
highlights the need for larger studies in the developing world. It is important to 
mention that it is difficult to draw specific conclusions when comparing different 
countries/ populations as the term “viral infection” or upper respiratory tract infection 
is not standardised.
Presentation 
Platelet count at diagnosis 
Various reports reveal that the mean platelet count at diagnosis can range from 7,3-
24 x 109/l.12,19,21-25  More than half of the patients in two studies, had platelet counts 
less than 10 x 109/l.19,21  Age, gender and  race was not shown  to have a significant 
effect on the presenting platelet count.19  
Presenting complaints 
Multiple studies have shown that the most common manifestation of ITP is 
cutaneous bleeding (i.e. bruising and petechiae), followed by mild 
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epistaxis.19,21,22,24,27,28 The frequency of severe bleeding is reported at around 3%,22 
with the risk of intracranial haemorrhage (ICH) reported to be lower than 1% (0.1- 
1%).22-24,29  
Lilleyman et al reported the incidence of ICH over a 20 year time period in a UK 
survey. Fourteen children were identified, and the circumstances around the 
diagnoses were analysed. The group reported an extrapolated annual incidence of 
0.1% in children with ITP. The platelet count of all patients was below <20 x 109/l. 
The study also revealed that 50% of the patients’ intracranial bleeds occurred more 
than 1 month after diagnosis, refuting previous thinking that the greatest risk for ICH 
is shortly after diagnosis. Additionally 50% of the patients had another contributory 
risk factor which may have precipitated the ICH.29  
 
The Relationship of the Platelet Count to symptomology   
Table1, adapted from a graph from a study published in the Lancet,20(fig 2) shows that 
despite having platelet counts less than 10 x 109/l, the majority of patients in this 
group still only have mild symptoms (180 out 425). Mild symptoms account for more 
than 70% of all “platelet count groups”.  
Table 1. Platelet count to severity in UK  








<10 x 109/l. 0.2% 42% 15% 3% 
10-19 x 109/l. 0.5% 19% 4% 0.2% 
20-50 x 109/l. 0.2% 10% 1% 0 
51-100 x 109/l 1% 3% 0.4% 0 
>100 x 109/l. 0 0.5% 0 0 
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*adapted from bar graph showing numbers of patients in each category; percentages 
calculated from n=425 
 
The severity of presentation of the disease has previously been measured by the 
degree of thrombocytopenia, however, it has been agreed upon by the ICIS group 
that severity should rather be correlated with bleeding symptoms.1,5   
Thus far, no standardised tool has been recommended. A novel bleeding severity 
tool used in the UK audits characterised bleeding as ‘Mild’, ‘Moderate’, ‘Severe’ and 
‘Life threatening or ICH’. (Table 2)22  
 
Table 2. Severity of bleed 
Mild Few petechiae and small (< 5cm) 
bruises; Epistaxis stopped with applied 
pressure. 
Moderate Numerous petechiae and large (>5 cm) 
bruises; Epistaxis longer than 20min. 
Intermittent bleeding from gums, lips, 
buccal, oropharynx or gastrointestinal 
tract. Hypermenorrhagia, haematemesis, 
haematuria, malaena without 
hypotension and falling of Hb <2g/dl. 
Severe Epistaxis requiring nasal packing or 
cautery. Continuous bleeding from gums, 
buccal, oropharynx. Suspected internal 




haematemesis, haematuria, malaena 
without hypotension and falling of Hb 
>2g/dl. 
Life threatening or intracranial 
haemorrhage(ICH) 
Intracranial haemorrhage or continuous 
or high-volume bleeding resulting in 
hypotension or prolonged capillary refill 
and requiring fluid resuscitation or blood 
transfusion (>10ml/kg) 
Based on this scoring tool, the UK audit (n=203) showed that 54% of patients studied 
were classified as mild, 42% as moderate and 4% as severe.  The children with mild 
ITP had less bleeding sites as compared to the moderate and severe group. In the 
“severe group “(8 children), only 1 child had an ICH.22 
 
Chronic ITP  
Chronic ITP (cITP) has a reported incidence of between 24- 31%.19,23,24  No factors 
have been shown to predict chronicity, however, factors such as an insidious onset, 
lack of preceding viral infection and an older age at presentation (i.e. >7 years), have 
been reported to have an association with cITP.19,24 
 
Diagnosis and investigations 
American (ASH) and British (BSH) guidelines take a similar approach to the 
diagnosis of ITP. 16,,30-31 The British Society for Haematology (BSH), make the 
diagnosis of ITP a diagnosis of exclusion, when history, examination and 
investigations do not suggest an alternate diagnosis.31-32 ASH updated their 1996 
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guideline in 2011 dispensing with the requirement for a bone marrow aspirate. They 
recommend diagnosing ITP in children with suggestive histories, examination 
findings of a petechial rash/purpura in an otherwise normal child, isolated low platelet 
count or sparse platelets on smear. If there are any atypical findings or suspicion of 
another disease process, then the diagnostic approach includes imaging, further 
laboratory tests and a bone marrow aspirate.30  
Bone marrow aspirates (BMA) 
Bone marrow aspirates (BMA) do not, in most instances, aid in the diagnosis of 
ITP.30 Calpin et al33 reviewed 484 patients that had BMAs to confirm ITP. No 
diagnoses of leukaemia were made post-BMA in the 332 children with typical 
heamatologic features of ITP. In the 152 with the provisional diagnosis of ITP with 
“atypical features” (152 children) 3 had leukaemia and 7 had aplastic anaemia. On 
review of the clinical presentation in the children with leukaemia, it was found that 
they had inconsistent features of ITP; and the patients with aplastic anaemia had 
other abnormal parameters on their blood film. The risk of missing the diagnosis of 
leukaemia in the setting of typical findings of ITP is less than 1%. Another study 
showed that it is unlikely for a child with leukaemia to present with only an isolated 
thrombocytopenia (0 cases in 2239 cases).34 Therefore both the American and 
British guidelines suggest BMA only in those patients that have an atypical course, 
are unresponsive to drug therapy or have other features making another diagnosis 
likely.30-32  
The incidence of BMA varies from 13-72%.21- 25, 35  The low rate of “13% BMA” is due 
to deliberate attempts by British centres to adopt a more conservative approach on 
the basis that BMAs do not aid in the diagnosis. Analysis from the UK Registry 
20 
comparing ‘proportion of children undergoing bone marrows’ from 1995 to 2000 to 
2009 showed a reduction from 40% to 18% to 13% respectively.21
 A study in Alabama, where 72% of patients (n=409) had bone marrow biopsies, 
reported that the bone marrow biopsy result did not alter the diagnosis or 
management of the patients.24 Similarly, a study in Ontario where 64% of patients 
(n=74) had bone marrow aspirates revealed that the diagnosis was not altered in any 
of the patients, even in those who had “Atypical ITP” (53% of those who had BMA).12  
A survey in 2008 by the Department of Paediatrics and Child Health at Tygerberg 
polled 101 doctors around South Africa in respect of their management approach to 
acute ITP in children. A large proportion of responders would first do a bone marrow 
aspirate before initiating steroid therapy and some would do one even if they were 
not considering steroids. Between 30-50% of responders would do a bone marrow 
aspirate; 30% for mild ITP and around 50% for moderate ITP (epistaxis, bleeding 
from oropharynx).36 Recommendations from the Indian Society of Haematology 
advocate a BMA before steroid initiation, as follow-up of patients cannot be certain in 
their social demographic.37 
Management 
Management options in the acute phase vary from expectant management (due to 
the high rate of spontaneous remission as well as rarity of serious bleeds38) to 
emergency interventions such as platelet transfusions (for life-threatening bleeds), or 
definitive treatments such as corticosteroids and immunoglobulins.  
A review by Cooper39 examined studies from different countries and the variability of 
treatment rates between countries. South Africa’s treatment rate was at 81%, 
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exceeded only by Canada at 90%. The UK’s rates were 16% in 2011, compared to 
previous rates of 61% in 1995, and 38% in 2003.32  
The dilemma to treat or to “watchfully wait” is often guided by the fear of ICHs.39  
More research is changing the previous non-evidenced based model, and as shown 
above, the UK is on a downward trend with regard to treating patients. Newer data 
has shown that “eventual normalisation of the platelet count happens regardless of 
the management chosen”.23,32,40-41 A multicentre study by the NOPHO-ITP Study 
Group showed that having policies that actively treat patients with “newly diagnosed 
ITP”, accelerated the platelet recovery, however it did not have any effect on the 
development of cITP or the morbidity at follow-up.42  
ASH recommendations have had a notable change from the 1996 ASH guideline. 
There has been a move away from treatment based on the platelet count.  This is in 
keeping with data that suggests that despite the presentation, platelet count and 
treatment most children do not experience severe bleeding.30,38 The BSH guidelines 
acknowledge that many children with very low platelet counts have minimal 
symptoms and usually have spontaneous remission within a few weeks. The 
guidelines also note that life-threatening haemorrhage is rare in children with ITP, 
regardless of the platelet count, and is not necessarily prevented by drug treatment. 
Therefore, children with acute ITP are managed expectantly. Mild cases are not 
admitted, but educated about the disease and the warning signs, and are informed to 
return at any time should the parents be concerned. The full blood count is repeated 
with 10 days to ensure a more serious disease process is not missed. The first line 




The Intercontinental Childhood ITP registry reported that the average rate of 
hospitalisation was 73%. In the patients who were “untreated”, 47% of these cases 
were still admitted for observation, and in the “treated” group, 85% of cases were 
admitted.23 The UK reported a lower rate of hospitalisation. In 2009, 43% of the 
children were admitted, with a median stay of 1-5 days.22
Treatment 
The aim of treatment is to reduce the risk of serious bleeding, without engendering 
treatment-related risks.39 
ASH suggests observation alone for children with mild bleeding. In children with mild 
bleeding where follow-up is uncertain, the child comes from far away, rest and low 
activity cannot be assured or there is an upcoming invasive procedure, treatment 
may be warranted.30,




Steroids are considered first line therapy.39,44   
Their mechanism of action is thought to be threefold. They inhibit phagocytosis and 
antibody synthesis, they improve platelet production and increase stability of the 
microvasculature.45
The Intercontinental Childhood ITP registry observational study showed that 33% of 
the patients treated received steroids. Corticosteroids have been shown to have a 
response rate of 70-80%.7,30,
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There is still debate with regard to dosing, however, shorter duration of steroids is 
now recommended. With prolonged use, the side effects of corticosteroids often 
outweigh their benefits. To avoid these complications, prednisone should always be 
rapidly tapered and stopped after a maximum of 4 weeks of therapy. The traditional 
regimen has been two milligrams per kilogram per day over 21days.30,44 
Four milligrams per kilogram per day for four days was shown to be more common 
practice in a Canadian study25. The International consensus report recommends 
prednisone to be used only to maintain a haemostatic platelet count, and for as short 
a time as possible. They report that the higher dose regimen (4mg/kg) has shown 
that 72% to 88% of children raise their platelet count to > 50 109/L within 72 hours.44 
 
 IVIG: 
Intravenous immunoglobulin (IVIG) is also considered part of the first-line therapy for 
ITP. It acts on both humoral and cellular immunity. They block the Fc receptors of 
macrophages in the reticulo-endothelial system thereby slowing the clearance of 
antibody-coated platelets.7,37,45 They also exert an effect by arresting maturation of 
dendritic cells, decreasing interleukin-12 production and increasing interleukin-10 
production.7,45  
The recommended dose ranges from 0.8-1g per kilogram per day as a single dose. 
The efficacy of IVIG is reported to be between 70-90%.7,30 The rise in platelets is 
rapid (rise within 24-48 hours). The Intercontinental Childhood ITP registry 
observational study showed that 29% of the patients treated received IVIG.   
Interestingly, in a Nordic study IVIG was used as the first line therapy over 
corticosteroids. Fifty one percent of treated cases received IVIG, compared to 5% of 
those who received corticosteroids. One percent of cases used both IVIG and 
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steroids. Similarly, Sutor et al reported a preference for IVIG. Sixty one percent of 
patients received IVIG, 19% corticosteroids, 6% both IVIG and corticosteroids and 
14% no treatment.21  
An audit by Bolton-Maggs and Moon in 1995 in the UK showed a discrepancy 
between published guidelines in 199246 and clinical practice. Amongst these was 
that IVIG  was  used commonly as first line therapy (23%), almost equivalent to 
corticosteroids (24%).21  A follow up audit was done in 2009 and showed that of 
those who received platelet-raising therapy, corticosteroids was the first line therapy 
(48%), then IVIG (28%) and combination therapy (24%). It also showed a high rate 
of expectant management (80%).20-22 
Among more common, non-life threatening side effects IVIG has been shown to 
have serious life-threatening side effects like anaphylaxis. In addition, it is costly and 
requires hospitalisation for infusion.  
 
 Anti-D immunoglobulin 
Anti-D used to be available as a front-line agent for the treatment of ITP.32 
Since 1996, numerous studies have examined the use of Anti-D vs. IVIG. In a 
randomised prospective study by Tarantino et al, a single dose of Anti-D (50 µg/kg or 
75 µg/kg), was compared to 0.8mg/kg IVIG. The data showed that a dose of 75µg/kg 
was superior to the lower dose of 50µg/kg.  However, this came at the expense of 
additional side effects. There was equivalent efficacy between Anti-D and IVIG; 
patients who received Anti-D, had a response rate of 71% within 24hours, and 98% 
within 72hours. Similarly patients receiving IVIG, had a response rate of 78% within 
24hours and 90% within 72hours.47   
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Common side effects of Anti-D include headaches, chills, nausea, vomiting and 
anaemia. Serious side-effects can occur. The FDA has issued a black box warning 
due to an increased risk of haemolysis and renal failure.30,32,37,39 
ASH recommends Anti-D, only in patients who are D- positive, who have a negative 
direct antiglobulin test (Coombs) and who have not undergone splenectomy.30 
 
 Second-line therapy: 
 
 Rituximab 
Rituximab is a second line agent that is used in the treatment of ITP. It is an anti-
CD20 monoclonal antibody that targets and destroys CD20+ B-lymphocytes.7,37,39,48-
49 Its Fc domain facilitates both complement and Ab-mediated clearance. It alleviates 
disease burden by removing or reducing the level of autoreactive B antibodies.48 
 A few studies have shown that the use of rituximab does show a response in the 
treatment of ITP. A systematic review of observational studies (n=323) showed a 
complete response (platelet count > 100 x 109/l) in 39% of patients, and a partial 
response (>30 x 109/l) in 68%.49 
Patel et al examined selected responders to rituximab to assess the duration of 
response 5 or more years from initial treatment. The sustained response to rituximab 
was estimated as 26% at 5-years.39,48 
Rituximab is shows potential as a “splenectomy sparing” drug 49 but there is a 
paucity of randomised control trials to help direct clinical practice. 
The ASH updated guideline recommends that it be considered in children where 
conventional treatment has failed, and who have ongoing, significant bleeds and/or 
to improve quality of life.30 Clinicians must always be mindful of the adverse effects 
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which include hypotension, rash, sore throat, fevers, rigors, neutropenia, long-term 
immunosuppression from hypogammaglobulinaemia and the potential for 
haematological malignancies.39,48-,49 
 
 Thrombopoeitin receptor agonists 
Thrombopoeitin receptor agonists (TPO-RA) are novel agents in the treatment of 
refractory ITP. They are considered game-changers in the treatment of chronic ITP. 
They stimulate the production of platelets but also are thought to have some immune 
modulating effect. They are believed to increase total circulating ‘transforming growth 
factor’ and reduce interleukin-2-producing CD4 cells. This in turn re-establishes 
immune tolerance.39,49  
There are two TPO-RAs registered. The first, romiplostim, is a synthetic recombinant 
protein- classified as a peptibody. This induces activation of the thrombopoeitin 
receptor.  The second, eltrombopag, is a small molecule that binds to the 
transmembrane domain, and not at the receptor site. It does not compete with TPO.. 
In early studies, Romiplostim was compared to placebo; there was a 88% response 
rate in the first study, and a 83% response rate in the second study.50-51  In both 
studies patients on the TPO-RA treatment arms had no side effects but the study 
sample was very small (n=22 and n=18 respectively).50-51  A randomised controlled, 
double blinded, placebo controlled study (n=62) was conducted by Tarantino et al.52 
They found that Romiplostim induced a high rate of platelet response as compared 
to placebo that was statistically significant and that the drug was safe in children. 52 
Eltombag has also been licensed for use in children with chronic ITP. It has been 
shown in a multi-country randomised controlled trial (PETIT2) to be effective in 
maintaining a platelet response with a safe side effect profile. The most common 
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side effect was raised hepatic aminoacid transferases. There were more adverse 
events in the placebo group than the treatment arm.53
Splenectomy 
The spleen is the main site where platelets are consumed by antibody recognition of 
the Fc receptor on macrophages within the reticuloendothelial system. Splenectomy 
in patients with cITP removes the mechanism of platelet destruction as well as a 
large source of antibodies.7,30,44
Both the international consensus paper by Provan et al 2010,44 and the updated 
ASH evidence-based guideline 2011 by Neunert et al,30 agree that a splenectomy, 
with appropriate previous vaccination, is an effective treatment modality in chronic 
refractory ITP. Five studies over the last 20 years have shown an overall response of 
71.5%.39 
However the decision to undertake a splenectomy in a child must not be taken 
without careful consideration. ASH recommends that splenectomy be reserved for 
children with significant or persistent bleeding who have failed to respond to other 
treatments.30 Provan et al argues that splenectomy is “rarely recommended in 
children because risk of death from ITP in childhood is extremely low ( 0.5%)” and 
the risk of post-operative sepsis outweighs the benefit.44
Conclusion 
The approach to the diagnosis and management of ITP has undergone considerable 
change over the last two decades. Nomenclature has changed and the management 
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now tends to follow evidence-based practice. New scientific research has also 
offered novel agents that can be used in patients with chronic disease. 
The ITP Working Group is collaborating to increase the number of study patients, to 
improve future practice and to standardise treatment protocols. 
The Haematology-Oncology Service at the Red Cross Children’s War Memorial 
Hospital has always advocated a more conservative approach akin to that adopted 
by the BSH. Local considerations have informed this approach. Poor social 
circumstances and lack of private transport frequently mandate admission in well 
patients but this has allowed clinicians to ‘watch and wait’ in many cases.  
A review of patients presenting to RCCWMH would be helpful to understand the 
local demography of patients with ITP, the natural history of the disease, and to 
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ABSTRACT 
Management of Paediatric Immune Thrombocytopenia at a South African 
centre from 1991-2011 
Shehnaaz Akhalwaya1, Ann Van Eyssen2, Marc Hendricks2 and Alan Davidson.2
1. Department of Paediatrics and Child Health, Red Cross War Memorial Children’s Hospital;
Faculty of Health Sciences, University of Cape Town
2. Haematology-Oncology Service.  Department of Paediatrics and Child Health, Red Cross War
Memorial Children’s Hospital;  Faculty of Health Sciences, University of Cape Town
Three hundred and seventeen patients meeting the diagnostic criteria for immune 
thrombocytopenia presented to Red Cross War Memorial Children’s Hospital 
between 1991 and 2011. We retrospectively reviewed these patients in order to 
describe patient demography, the natural history of the disease, and different 
approaches to diagnosis and management. There were 162 males and 155 female 
patients. The median age of onset was 3.48 years old (IQR 1.66-6.36).  In the 4 
weeks preceding presentation, 98 (31%) patients had a viral illness. The median 
presenting platelet count was 7 x 109/L (IQR 3-14.5). Petechiae were the most 
common clinical sign at presentation (58%; 184/317). None of the patients presented 
with intracranial haemorrhages. The majority of patients in the study were admitted 
(234/317; 74%) with a median stay of 4 days (IQR 0-6). Bone marrow aspirates 
(BMA) were performed in 188 patients (59%). There was a reduction in BMA from 
1991-2000 to 2001-2011 (p<0.001). There was an increase in the percentage of 
patients treated from 1991-2000 (77/170; 44%) to 2001-2011 (99/147, 67% p< 
0.001). Resolution occurred in 75% of patients with a median time to resolution of 31 
days (IQR 11-73 days).  When we analysed the “survival estimate” from the 2 
decades, despite differing rates of BMA, treatment rates and regimens, there was no 
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Immune Thrombocytopaenia (ITP) is an immune mediated disorder, characterised 
by loss of self tolerance. ITP is defined as a platelet count less than < 100 x 109/l, 
and is caused by autoantibodies, usually IgG, directed against platelet membrane 
antigens e.g. glycoprotein IIb and IIIa.1-3 Autoantibodies may be directed against 
megakaryocytes as well reducing platelet formation. There is also evidence of T-cell 
cytotoxity in the pathogenesis of ITP. 3 
A common cause of isolated thrombocytopenia in childhood, ITP has seen vast 
changes in definition, diagnosis and management in the last decades. As research 
has enabled us to understand more about ITP, the need for standardisation has 
become apparent.  
 
The incidence of ITP is estimated at between 1.9 to 6.4 per 105 children per year.4 
The mean age of onset with children registered in the ICIS Registry 1 was 5.7 years 
42 
 
(5.9 years for girls, 5.5 years for boys)5 and the mean platelet count at presentation 
ranged from 7.3-24 x 109/l.6-12 The most common manifestation is cutaneous 
bleeding, followed by mild epistaxis.7-9,11,13,14 The frequency of severe bleeds is 
around 3%,20 with a risk of intracranial haemorrhage (ICH) at lower than 1% (0.1- 
1%). 9-11,15  
 
A diagnostic approach emphasises the clinical picture in a context of isolated 
thrombocytopenia.16 Both the updated American (ASH) and British Society for 
Haematology (BSH) guidelines suggest that bone marrow biopsies (BMA) are only 
necessary in those patients that have an atypical course, are unresponsive to drug 
therapy or have features making another diagnosis likely.16-17 Despite this the 
incidence of BMA in newly diagnosed ITP varies from 13-72%.8-12,18  
 
Acute management options vary from expectant management (due to the high rate 
of spontaneous remission as well as rarity of significant bleeding) to emergency 
interventions such as platelet transfusions (for life-threatening bleeds), or treatments 
such as corticosteroids and immunoglobulins. The dilemma to treat or to “watchfully 
wait” is often guided by the fear of ICHs.19,20 
 
ASH recommendations have had a notable change from the 1996 ASH guideline. 
There has been a move away from treatment based on the platelet count.  This is in 
keeping with data that suggests that despite the presentation, platelet count and 
treatment most children do not experience severe bleeding. ASH suggests 
observation alone for children with mild bleeding..16 Similiarly, the BSH guidelines 
acknowledge that many children with very low platelet counts have minimal 
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symptoms and usually have spontaneous remission within a few weeks. Since life-
threatening haemorrhage is rare in children with ITP, regardless of the platelet count, 
and is not necessarily prevented by drug treatment, most children with acute ITP can 
be managed expectantly.17 
 
To date, most of the guidelines for ITP have been written by and for developed 
countries. The place of a developing country in Sub-Saharan Africa, with potentially 
different needs, demographics and resources has not been addressed. The aim of 
this study was to review patients presenting to the Red Cross War Memorial 
Children’s Hospital (RCWMCH) in Cape Town, to determine the patient demography 
and the natural history of the disease, as well as to examine our approach to 




This was a retrospective document review. Prior to the research, ethics approval was 
obtained from the University of Cape Town Human Research Ethics Committee. 
(623/2013) 
 
The RCWMCH is the only children’s hospital in southern Africa, and is one of two 
tertiary referral sites for paediatric patients in Cape Town, Western Cape. The 
population in the city of Cape Town is 3 740 026. In 2015, it was estimated that 26% 
of children in the Western Cape live under the poverty line (less than ZAR671 per 
month i.e. less than USD50 per month).21,22 The gross national income per capita of 
South Africa is USD 6050 as compared to the United States at USD 54960 and the 
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United Kingdom at USD 43340.23  Most cases of ITP are referred to the Haematology 
Oncology service at RCWMCH from primary and secondary level hospitals in the 
state sector, or from private practitioners. Once the diagnosis is made and 
management initiated these patients are usually down referred to their closest point 
of care, but may be referred back if complications occur.  
 
The institutional database of all patients with ITP since 1951 to present was 
searched. All patients diagnosed with ITP from 1991 to 2011 were examined and 
audited. All patients were given numerical identifiers to maintain patient 
confidentiality. Data was entered into a Microsoft AccessTM database, and included 
identifying data, co-morbidities, clinical information around bleeding, full blood count 
at presentation, platelet counts at various intervals, treatment and outcome. 
(Appendix 1) 
 
Complete resolution was defined as a platelet count > 100 x 109/l. Chronic ITP (cITP) 
was defined as persistence of thrombocytopenia greater than 12 months (this 
definition has been changed from 6 months by the International ITP working group 
because there is still a good chance of spontaneous resolution after 6 months).24 
Relapse was defined as a platelet count >100 x 109/l but relapsing to a count less 
than 100 x 109 /l within 12 months. The administered dose of steroid was either 
stated as mg/kg/day or was calculated.  
 
This was a descriptive study. Success of treatment outcomes were analysed using 
StatisticaTM. Children treated for ITP at the RCWMCH were divided into two cohorts: 
1991 to 2000 and 2001 to 2011. Where the 2 groups or treatments were compared 
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Three hundred and fifty three folders were evaluated. (Figure 1) Thirty six patients 
were excluded from analysis because they had non-immune forms of 
thrombocytopenia or secondary immune thrombocytopenia (28), inadequate records 
(6), or were involved in a clinical trial (2) (Appendix 2). A total of 317 patients were 
included in the analysis. The median age of onset in the study group was 3.48 years 
(IQR 1.66-6.36). The majority of children (72%) were less than 6 years old. There 
were 162 males [median age 3.4 (IQR 1.42-6.55)] and 155 females [median age 
3.54 (IQR1.77-6.32)]. When stratified into those under 5 years old and those older 
than 5, the gender distribution was not statistically different.  
 
A large number of patients had co-morbidities (92/317; 29%). Nineteen had iron 
deficiency anaemia, which was presumed when a patient had a haemoglobin (Hb) of 
< 11 g/dl and MCV <75 fL (Appendix 3). In the 4 weeks preceding presentation, 98 
(31%) patients had a viral illness. Only 6 patients (2%) had received vaccinations 
before the onset of illness.  
 
On presentation, the median platelet count was 7 x 109/l (IQR 3-14.5), with a median 
Hb of 11.2g/dl (IQR 9.9-12). Most patients (196/317) had platelet counts below 10 x 
109/L. Table 1 summarises the patient characteristics, management and outcome 
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between the two decades. In the second decade 2001-2011, patients presented with 
lower platelet counts with a median of 5 x 109/L (IQR 3-12 p=0.002). 
More than half the patients (58%; 184/317) presented with petechiae. Fourteen 
percent (45/317) presented with epistaxis; 5% (15/317) with gastrointestinal bleeds 
and 4% (12/317) with haematuria (macroscopic). None of the patients presented with 
ICH. Nineteen percent (61 patients) presented with “other” symptoms; mouth bleeds 
(16/317, 5%) were the most common presentation followed by trauma (7/317, 2%), 
sub-conjunctival bleeds (5/317, 1.6%) and in 4 patients (1.2%) ITP was an incidental 
finding. 
When bleeding (during the course of the patients’ illness) was classified according to 
the bleeding severity tool suggested by Bolton-Maggs,25 mild bleeds were seen as 
the most prevalent (Table 2). When platelet count was compared to severity the 
majority of patients with platelets <10x109/l were mild or moderate (Table 3). In the 
case of life threatening bleeds (5/317); 3 patients were less than 5 years old: 1 had a 
GIT bleed and 1 presented in shock with a purpuric rash. The third patient (2 years 
old) presented with epistaxis and lobar pneumonia. Her profound thrombocytopenia 
resolved within a month but she relapsed 9 months from diagnosis and developed an 
ICH 2 months after the relapse. She was found to have a right temporal 
haemorrhage, which she survived. She did not have any long term neurological 
sequelae. She was treated with IVIG, pulsed with methylprednisone and received a 
platelet transfusion. The other 2 patients were both 11 years old; 1 had haematuria, 
and the second, who had initially presented with petechiae and mild bleeding, 
presented 7 months later with an ICH. Imaging revealed a temporal intra-cerebral 
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bleed. The patient survived with a mild residual right hemiplegia. She was treated 
with 4mg/kg of oral prednisone, IVIG and received a blood and platelet transfusion. 
 
The majority of patients in the study were admitted to hospital (234/317; 74%) with a 
median admission stay of 4 days (IQR 0-6). BMA were performed in 188 patients 
(59%). Of those (188 patients), 82% were admitted and 60% received treatment. 
BMA were done with greater frequency in patients with lower platelet counts, lower 
haemoglobin, in those with co-morbidities which includes patients with iron 
deficiency anaemia (Table 4). BMAs were also more often performed in those with 
increased ‘severity of bleed’ score (Table 2). When looking at 1991-2000 as 
compared to 2001-2011 there has been a reduction in the number of BMAs which 
shows statistical significance (Table 1 -2). 
 
More than half the children in the cohort (175/317; 55%) were treated. In the 
“untreated” group 71% were admitted and in the “treated” group 77% of cases were 
admitted. Patients were treated in accordance to their bleeding score as seen in 
Table 2. All patients that had life-threatening bleeds were treated. There was an 
increase in the percentage of patients treated from 1991-2000, (68/156; 43%) as 
compared to 2001-2011 (107/161; 67%, p< 0.001) (Table 1). 
 
The most common treatment modality used was oral steroids (162/175; 91%) and of 
those (where the oral dose administered is known [n=153]) 52% (79/153) received a 
dose of 4mg/kg for 4 days and 48% (74/153) received 2mg/kg for 2 weeks. Four 
patients received intravenous steroids (methyl-prednisone, dexamethasone or 
hydrocortisone). When we looked at the difference in dosage per decade, we found 
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that 90% of patients that received 2mg/kg were in 1991-2000, whereas 73% of 
patients received 4mg/kg in 2001-2011 (p<0.001). Sixteen children received IVIG (11 
of whom also received steroids) and 1 received rituximab. This patient had 22q 
deletion syndrome with T-cell deficiency and rituximab was given during the chronic 
phase of his disease with no response to other modalities. 
Six percent of all patients (9/317) required a blood transfusion, and 7 percent 
(23/317) required a platelet transfusion; in all cases for severe or life-threatening 
haemorrhage. 
 
The outcome of 7 patients was unknown as 5 were lost to follow up and 2 were 
transferred (Figure 1). Resolution of ITP within 1 year occurred in 75% of the 
patients (237/317 patients) with a median time to resolution of 31 days (IQR 11-73 
days). Figure 2 shows the rise in platelet count over time, until complete resolution. 
As seen in the Figure 3-A, there was no statistical difference in time to resolution 
between those patients that had “no treatment” (median of 34 days) as compared to 
those who received treatment (median of 27 days) (p=0.3). More patients that did not 
receive treatment [79% (112/142)] resolved, as compared to those [62% (109/175)] 
that received treatment, although this was not statistically significant. In each of the 
bleeding score categories the proportion of cases that resolved was: Mild 71% 
(121/171), Moderate 67% (83/123), Severe 89% (16/18) and Life Threatening 20% 
(1/5). There was no difference in time to resolution if a patient presented with a 
platelet count of less than 10 x 109/L (Figure 3-B). 
 
Thirty-one patients relapsed (7%) with a median time to relapse of 231 days (IQR: 
109-303). Approximately two thirds of these the patients (20) went on to become 
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chronic, with 11 resolving. There was no difference in BMA rates in those who had 
relapsed and those who did not. There was a difference (p<0.001) in the rate of 
relapse between the two decades (Table 1).  
 
Out of the total of 317 patients, 93 patients (29%) went on to become chronic. In the 
chronic ITP cohort, the mean age was 4.35 years old (IQR 2.47-8.44). There was no 
difference in gender distribution in this group of patients. Patients with chronic ITP 
(cITP) were less likely to present with a preceding viral illness (p<0.001). The platelet 
count (11 x 109/L, IQR 5-20) on admission was noted to be higher than those with 
acute ITP (6 x 109/L, IQR 3-12; p<0.001). Figure 2 shows the difference of “rise in 
platelets over time” as compared to those who resolved. BMA were done in 74% of 
patients (p=0.001) and 72% of patients (65/93) with cITP received treatment.  
 
Refractory ITP was seen in 27 patients. Refractoriness was defined as no response 
to steroids and/or IVIG. A total of 19 patients underwent splenectomies (17 had 
refractory ITP; p<0.001). The time to splenectomy was a median of 796 days; with a 
response rate of 53% (10/19). Response to splenectomy was defined as a platelet 
count of > 100 x 109/l . The median age at splenectomy was 8.76 years old (IQR 
6.37 to 11.65). There was no statistical difference in the age of responders to non-
responders. 
 
Overall when we analysed the “survival estimate” from the two decades, despite 
differing rates of BMAs, treatment rates and regimens, there was no statistical 




The mean age of onset with children registered in the ICIS Registry 1 was 5 years 8 
months old.5 The peak age distribution was between 1 to 6 years old. Other studies 
have reflected similar demographics.7,9 The patients that are seen at Red Cross War 
Memorial Children’s Hospital reflect that of the findings of the ICIS registry regarding 
age. 
Most studies have shown that in younger age groups i.e. 1 to 5 years old, boys 
predominated over girls.5,8-10 The older children either, had an equal representation 
of boys to girls,7,8 or a slight predominance of girls (0.8:1).9  We found no difference 
between the incidence of girls and boys even when we stratified for age.  
Infections are known to be one of the triggers for ITP.6 There is little data from 
developing countries with regard to infection rates, and one might expect the 
incidence to be higher, but a study of Vietnamese children (n=82) showed a low 
incidence of infection (15%) preceding the onset of ITP.6 In our cohort 98 out of 317 
had preceding viral illnesses (31%) which is higher than the Vietnamese study but 
lower than Canadian studies (57%).12 
The mean platelet count on presentation in our cohort was 12.6 x 109/l, however the 
median count was 7 x 109/l, better reflecting the large number of patients who have 
very low counts on presentation. The literature similarly shows a mean platelet count 
ranging from 7.3-24 x 109/l.6-12 More than half the patients in 2 large studies had 
platelet counts less than 10 x 109/l.7,8   
When our patients were classified according to the bleeding severity score tool 
proposed by Bolton Maggs9 mild bleeds were the most prevalent (54%) even in 
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those with low platelet counts (Table 3), but less common than in the UK where 75% 
of patients presented with mild bleeds; less than 6% with severe bleeds and none 
with an ICH as a presenting symptom. We had a higher incidence of moderate (39%) 
and severe bleeds (5.5%) in comparison to the UK data (20% and 3% respectively) 
and 5 patients (1.5%) had life threatening bleeds (Table 2-3, Table 5 adapted from 
graph from the Lancet13,25 (fig 2)).  Interestingly, of the patients that had life-threatening 
bleeds, 4 out of the 5 went on to become cITP and 3 required splenectomies. Two of 
the patients had ICHs, 8 and 10 months into the course of the disease. Fortunately, 
they were not left with significant morbidity. 
Table 5: Platelet count to severity in UK (n=425) 








<10 x 109/l. 0.2% 42% 15% 3% 
10-19 x 109/l. 0.5% 19% 4% 0.2% 
20-50 x 109/l. 0.2% 10% 1% 0 
51-100 x 109/l 1% 3% 0.4% 0 
>100 x 109/l. 0 0.5% 0 0 
*adapted from bar graph showing numbers of patients in each category; percentages
calculated from n=425
It would seem that the patients seen at our institution are clinically more severe than 
those managed in the UK. A possible explanation for this is that, the referral pathway 
over the last decade has changed where clinicians in secondary hospitals and 
private facilities manage mild cases of ITP, thus skewing the distribution of patients 
seen at our facility. The difference in certain intrinsic (e.g. gene mutations affecting 
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immune response, ethnicity) and extrinsic factors (e.g. infectious disorders, recent 
vaccines or drugs) may also contribute.6  
 
The Intercontinental Childhood ITP registry reports that the average rate of 
hospitalisation is 73%. In the patients that were “untreated”, 47% of these cases are 
still admitted for observation, and in the “treated” group 85% of cases are admitted.10 
The UK has a lower rate of hospitalisations. In 2009, 43% of the children were 
admitted, with a median stay of 1.5 days.9 The rate of admission in our cohort of 
patients was 70%. This is higher than the UK rates but aligns with the 
Intercontinental Childhood Registry. This may be as a result of us seeing patients 
that are clinically more severe based on the comparison of “bleeding score” as 
mentioned earlier. Social reasons also contribute to our higher admission rates. Our 
patients have poorer access to healthcare and education, are multi-lingual which 
creates potential language barriers and have poorer access to reliable transport and 
are therefore frequently admitted as a precautionary measure in case they suffer 
severe haemorrhage in the acute phase.  
 
It is worth noting that there are important differences in methodology between 
Intercontinental Childhood Registry5, UK review9 and this study. The Intercontinental 
Childhood Registry namely Registry I was the first project of ICIS. Coordinators and 
investigators from across the world were recruited. Newly diagnosed patients were 
registered by their institution on a case by case basis. Once patients were 
registered, then the investigators were sent questionnaires that looked at 
presentation of ITP, demographics, natural history and nature of disease.5  
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The UK study by Grainger et 9 extracted data from the UK Childhood ITP registry, 
and compared the results to an audit in 1995 and 2000. Those audits were 
conducted by postal questionnaire. The classification of ‘severity of bleed’ was made 
by the reporting clinician not by the data analysts as is the case in this study. 
 
The incidence of bone marrow aspiration varies from 13-72%.8-12,18 Analysis from the 
UK Registry comparing ‘proportion of children undergoing BMA’ from 1995 to 2000 
to 2009 showed a reduction from 40% to 18% to 13% respectively.8 This reduction 
reflects a more conservative approach because it has been shown to be 
unnecessary.26 US studies show a different approach but no added benefit from 
doing BMA more frequently. 
 A study from Alabama where 72% of 409 study patients had BMA, reported that the 
bone marrow aspirate result did not alter the diagnosis or management of the 
patients.11 Similarly a study in Ontario12 with 74 patients, 64% had BMA. The 
diagnosis was not altered in any of the patients, even in those who had “Atypical 
ITP” (53% of those who had BMA).  
We have performed BMAs in 188 cases (59%). This is more than the patients in the 
UK registry but less than the patients reported in Northern American series. The 
patients presenting with low haemoglobins are a reflection of the high incidence of 
iron deficiency anaemia in our population, rather than bleeding on presentation or 
chronic blood loss. A study in 2002 reported the prevalence of anaemia between 
64% - 83% of children. Iron-deficiency anaemia was found in 32%-46%.27 It was 
found that in this group of patients more BMA were performed (22.8% vs. 13.2%). It 
may suggest that BMA are performed more readily as the clinician had a heightened 
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concern for a secondary cause when two or more haemopoetic “cell lines” were 
affected. Patients with platelet counts less than 10 x 109/L, and with co-morbidities 
were also more likely to have BMA performed. However these did not show not 
statistical significance. We observed that BMA frequency increased with severity of 
bleeding, and this did show statistically significance (p=0.008) (Table 4). 
Despite the higher numbers of BMA performed at RCWMCH compared to the UK, 
there has been a reduction over time. The haematology oncology service at 
RCWMCH has endeavoured to align itself with a more conservative approach by 
minimising “unnecessary” invasive procedures and this is reflected in the study. In 
the years 1991-2000 61.7% of patients underwent BMA compared to 2001-2011 
when the proportion fell to 38% (p<0.001). 
 
Chronic ITP in our study was present in 29% of patients. This is in line with studies 
that show an incidence of between 24- 31%.7,10,11 We found that our patients were 
less likely to present with a preceding viral illness (p<0.001) and also had a higher 
platelet count on presentation. The age of presentation was not in keeping with 
previous studies that showed an association with older age (i.e. >7 years).7,11 
 
A review article in The British Journal of Haematology examined studies from 
different countries, and the variability of treatment rates between countries. The 
treatment rate reported for South Africa was 81%,28 exceeded only by Canada at 
90%. The UK’s rates were 16% in 2011, compared to previous rates of 61% in 1995, 
and 38% in 2003.20 The rate for South Africa was based on a single institution study 
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at Tygerberg Hospital in Cape Town which reviewed 106 patients over 10 years from 
1996 to 2006.28
The findings of our study show that over the last 20 years we have a considerably 
lower treatment rate of around 55%. But it must be said that our rates of treatment 
increased from 44% in 1991-2000 to 67% in 2001-2011. (p<0.001)  There was no 
difference in admission rate, and the patient profile was similar (Table 1).  
Looking at treatment modalities, 166 (95%) of the 175 children who were treated 
received steroids and 16 (9%) received IVIG, including 11 who received both.  
The Intercontinental Childhood ITP registry observational study showed that 33% of 
the patients treated received steroids with a response rate of 70-80%.2,16,19 The 
traditional regimen has been 2mg/kg per day over 10-14days.16,19 Four mg/kg per 
day for 4 days was described in a Canadian study12 and is now the recommended 
approach. This higher dose regimen is effective in that 72% to 88% of children raise 
their platelet count> 50 109/l within 72 hours. 29 and is intended to limit the window of 
exposure to steroids and their side effects (hypertension and glucose intolerance). 
From 2001 the use of the higher dose prednisone regimen (4mg/kg for four days) 
became common practice at RCWMCH. It was used in 72% of cases, whereas in 
1991-2000 90% of patients received the 2mg/kg/day regimen. There was no 
difference in resolution rates between the two dosages (p=0.6). There has been no 
evidence to support either dosing regimen over the other.8,16,30  
In the 2009 UK survey by Grainger, corticosteroids are used most commonly as first 
line therapy (48%), followed by IVIG (28%). Expectant management in the survey 
was at 80%.9  By comparison, Nordic18 and German8 studies showed IVIG used as 
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the first line therapy over corticosteroids. The preference for IVIG is due to a more 
rapid rise in platelet count (often within 24 hours) with equal efficacy of between 70-
90%. 2,19 
Albeit an effective agent in the management of ITP, IVIG is not without potential side 
effects some of which may be potentially life-threatening viz. anaphylaxis. 
Considering the huge differential in cost between oral prednisone and IVIG and the 
fact that in our setting extreme cost of drugs can be prohibitive, we have historically 
been judicious with its use, in the face of a much cheaper alternative. In addition to 
cost, it also requires hospitalisation for administration. Consequently only 16 of our 
patients received IVIG.  
 
When looking at the relapse rate, there was a statistical difference between the two 
decades with less patients relapsing from 2001 onward. The time to response as 
well as percentage of children that reached complete resolution did not change 
between the two decades further emphasising that despite treating a higher 
percentage of patients there was no change in the time to resolution. This is a 
reassuring finding which supports an approach of “watchful waiting”. We have 
observed that ITP is a benign, self limiting disease. We have had no deaths, and 







This study has allowed us to better understand the demography of patients seen at 
RCWMCH. We have shown that key patient characteristics are similar to those 
reported in the literature. We have shown that lower platelet counts should not be the 
only factor taken into account when deciding on treatment, but that the severity of 
bleeding can also be therapeutically instructive.  
 
It appears that we fall in the middle of the management divide between the American 
and British guidelines.  Our higher admission rates mostly speak to our patient 
demographic who have poorer access to reliable transport, resources and 
healthcare. We are reassured that we are keeping abreast with international 
guidelines of adopting a more conservative approach to BMA, thereby minimising 
patient discomfort, procedural risks and reducing costs without compromising 
outcome.  Unexpectedly we found that our treatment rates have risen and this may 
be accounted for by severity in bleeding due to changes in referral pathways. Our 
data supports the contention from other sources that a “watchful waiting” has similar 
outcomes to patients receiving treatment. The favourable outcomes seen in patients 
with ITP, despite very low platelet counts and even moderate to severe bleeding, 
reinforces the idea that this condition is largely self-limiting, and empowers us to 
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Figure 2.  Rise of platelet count at varying time intervals.  










Figure 3. Kaplan Meier Survival Estimates (A) Time to resolution comparing 
treatment vs. no treatment. (B) Time to resolution when comparing platelet count 










Table 1. Patient Characteristics comparing 1991-2000 to 2001-2011 
 









   
Male Sex 79 (49.4) 79 (50.6) 0.87 
Age (years) 3.8 (1.7–6.5) 3.1 (1.6–6.1) 0.22 
Viral illness 50 (32.1) 48 (29.8) 0.67 
Platelet count 
on diagnosis 
10 (4–17) 5 (3–12) 0.002 
Management:    
Admitted 118 (75.6) 116 (72.1) 0.47 
Received 
treatment 
68 (43.6) 107 (66.5) <0.001 
 Steroids 63 (40.4) 103 (64.0) <0.001 
 IVIG 8 (5.1) 8 (5.0) 0.95 
Platelet 
transfusion 
6 (3.9) 17 (10.6) 0.02 
Blood 
transfusion 
10 (6.4) 9 (5.6) 0.76 
Bone marrow 
biopsy 
115 (73.7) 73 (45.3) <0.001 
Splenectomy 8 (5.1) 12 (7.5) 0.72 
Outcomes:    
Resolved  
(within one year) 
113 (72) 124 (78) 0.28 
Relapse 20 (13) 11 (6.8) <0.001 
Refractory ITP 7 (4.5) 20 (12.4) 0.01 




























14.18 n=82, 48% n=87, 51%   
Moderate n=123, 
39% 
11.2 n=72, 59% n=83, 67%   
Severe n=18, 5.5% 10.7 n=15, 83% n=14, 72%   
Life-
threatening 















< 10 n=188 n=96 (30%*) n=73 (23%) n=15 (5%) n=4 (1.3%) 
10-19 n=71 n=38 (12%) n=31 (9.8%) n=2 (0.6%) 0 
20-50 n=45 n=27 (8.5%) n=17 (5.4%) 0 n=1 (0.3%) 
>50 n=13 n=10 (3.2%) n=2 (0.6%) n=1 (0.3%) 0 
*percentages calculated from total patients (n=317)  
 
 
Table 4. Bone Marrow Aspirates 
N=317 Biopsy Total 
188 
 
No Biopsies  
129 
 
Plts < 10 121 (64.4%) 75 (58.1%) P=0.263 
Hb <10 64 (31.9%) 
 





45 (34.9%) p=0.008 
Co-morbidities 63 (33.5%)  
 
29(22.5%) p=0.034 
Iron def Anaemia 43 (22.8%) 
 













Appendix 1: Data sheet 
 
ID   
Folder number number  
Name text  
Surname text  
Date of birth date  
Date of diagnosis date  
Age at Diagnosis DoD - 
DoB 
 






Yes/no Within 14 days 







Platelet count number  
Hb number  
MCV  number  
WCC number  
Severity of bleeds 
20 
number 1-mild Few petechiae and small (<5 cm) bruises. Epistaxis, 
stopped by applied pressure 
  2-moderate Numerous petechiae and large (>5 cm) bruises. 
Epistaxis longer than 20 min.  
Intermittent bleeding from gums, lips, buccal,  
oropharynx or gastrointestinal tract. 
  3-severe Epistaxis requiring nasal packing or cautery. 
Continuous bleeding from gums, buccal, oropharynx.  
Suspected internal haemorrhage  
(lung, muscle, joint, others). 
  4-life threatening or inter cranial bleed Intracranial haemorrhage 
or continuous or high-volume bleeding 
 resulting in hypotension or prolonged capillary refill and 








No treatment Yes/No  
Steroid Yes/No  
Type of steroid Text  
Dose of steroid number  mg/kg 
Anti-D Yes/No  
Rituximab Yes/No  
Blood transfusion Yes/No  
Platelet transfusion Yes/No  
Days of admission number  
OUTCOME   
Platelet count at 
diagnosis 
Number   




Platelet count in 4 
weeks 
number 
Platelet count in 6 
weeks 
number 
Platelet count in 6 
months 
number 
Date of resolution Date 





Date of Relapse / 
Date Last Seen 
Date 





Refractory ITP Yes/no 

















Diagnoses excluded from analysis Number 
File not found/incomplete 6 
Tuberculosis 14 
Part of clinical trial 2 
Hepatitis B 2 
Human immunodeficiency viral infection 2 
Von willebrand disease 1 
Diagnosis outside of the 20 year study range 1 
Bernard soulier syndrome 1 
Cytomegalovirus infection 1 
Hepatitis A 1 
Hereditary thrombocytopenia 1 
Post transplant 1 
Systemic lupus erthymatosus 1 





Iron deficiency anaemia 60 
Asthma 8 
Acute gastro enteritis 5 
Lower respiratory tract infection 4 
Impetigo 3 
Mumps  3 
Epilepsy 2 
Tuberculosis exposed 2 
Otitis media 2 
Allergic Rhinitis 2 
Ventricular-Peritoneal shunt-hydrocephalus 1 
Upper respiratory tract infection, diarrhoea and vomiting 1 
Upper airway obstruction 1 
Tonsillitis 1 
Tinea capitis 1 
Congenital bilateral ptosis 1 
Trisomy 21, Gastro-oesophageal reflux disease 1 
Spastic quadriparesis 1 
Scalp infection 1 
Scabies 1 
Rheumatic heart disease 1 
Q22 deletion, Cerebral-vascular accident, T-cell immunodeficiency 1 
Pelvi-ureteric junction obstruction with UTI 1 
Previous tuberculosis 1 
Pre septal cellulitis 1 
Physical abuse 1 
Parasuicide 1 
Chronic gastroenteritis 1 
Obese 1 
Axillary abscess 1 
Lice 1 
Left renal agenesis, maternal chronic ITP 1 
Kwashiorkor , Seizure 1 
Atopy, eczema 1 
Insulin dependent diabetes mellitus, hay fever, spasmodic croup annually 1 
Herpes stomatitis 1 
Heterozygous haemoglobin E 1 
Gingivitis 1 
Foetal alcohol syndrome 1 
Escherichia coli (E.Coli) urinary tract infection 1 
Dysmorphic, Patent ductus arteriosus 1 
Dog bite 1 
Developmental delay, social problems 1 
Dilated cardiomyopathy, Molluscum 1 
Chronic suppurative otitis media 1 
Constipation 1 
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Appendix 4: Authors guideline “Blood” 
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